These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20126478)

  • 1. Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
    Langenberg MH; Witteveen PO; Lankheet NA; Roodhart JM; Rosing H; van den Heuvel IJ; Beijnen JH; Voest EE
    Neoplasia; 2010 Feb; 12(2):206-13. PubMed ID: 20126478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
    Mross K; Drevs J; Müller M; Medinger M; Marmé D; Hennig J; Morgan B; Lebwohl D; Masson E; Ho YY; Günther C; Laurent D; Unger C
    Eur J Cancer; 2005 Jun; 41(9):1291-9. PubMed ID: 15939265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer.
    Thomas AL; Morgan B; Horsfield MA; Higginson A; Kay A; Lee L; Masson E; Puccio-Pick M; Laurent D; Steward WP
    J Clin Oncol; 2005 Jun; 23(18):4162-71. PubMed ID: 15867205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
    Thomas AL; Trarbach T; Bartel C; Laurent D; Henry A; Poethig M; Wang J; Masson E; Steward W; Vanhoefer U; Wiedenmann B
    Ann Oncol; 2007 Apr; 18(4):782-8. PubMed ID: 17218488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors.
    Chiorean EG; Malireddy S; Younger AE; Jones DR; Waddell MJ; Sloop MI; Yu M; Hall SD; Schneider B; Sweeney CJ
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):441-8. PubMed ID: 20091169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma.
    Brandes AA; Stupp R; Hau P; Lacombe D; Gorlia T; Tosoni A; Mirimanoff RO; Kros JM; van den Bent MJ
    Eur J Cancer; 2010 Jan; 46(2):348-54. PubMed ID: 19945857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase IA, open-label, dose-escalating study of PTK787/ZK 222584 administered orally on a continuous dosing schedule in patients with advanced cancer.
    Drevs J; Medinger M; Mross K; Fuxius S; Hennig J; Buechert M; Thomas A; Unger C; Chen BL; Lebwohl D; Laurent D
    Anticancer Res; 2010 Jun; 30(6):2335-9. PubMed ID: 20651389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of vatalanib (PTK/ZK) in combination with bevacizumab in patients with refractory and/or advanced malignancies.
    Jones SF; Spigel DR; Yardley DA; Thompson DF; Burris HA
    Clin Adv Hematol Oncol; 2011 Nov; 9(11):845-52. PubMed ID: 22252616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors.
    Langenberg MH; Witteveen PO; Roodhart JM; Verheul HM; Mergui-Roelvink M; van der Sar J; Brendel E; Laferriere N; Schellens JH; Voest EE
    Clin Cancer Res; 2010 Apr; 16(7):2187-97. PubMed ID: 20233884
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
    Lin CC; Calvo E; Papadopoulos KP; Patnaik A; Sarantopoulos J; Mita AC; Preston GG; Mita MM; Rodon J; Mays T; Yeh IT; O'Rourke P; Takimoto CH; Dancey JE; Chen H; Tolcher AW
    Cancer Chemother Pharmacol; 2009 May; 63(6):1065-71. PubMed ID: 18795291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors.
    Zhu M; Molina JR; Dy GK; Croghan GA; Qi Y; Glockner J; Hanson LJ; Roos MM; Tan AD; Adjei AA
    Invest New Drugs; 2020 Dec; 38(6):1755-1762. PubMed ID: 32328844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors.
    Chiorean EG; Hurwitz HI; Cohen RB; Schwartz JD; Dalal RP; Fox FE; Gao L; Sweeney CJ
    Ann Oncol; 2015 Jun; 26(6):1230-1237. PubMed ID: 25787923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors.
    Wang F; Molina J; Satele D; Yin J; Lim VS; Adjei AA
    Invest New Drugs; 2019 Aug; 37(4):658-665. PubMed ID: 30382439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
    O'Reilly T; Lane HA; Wood JM; Schnell C; Littlewood-Evans A; Brueggen J; McSheehy PM
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):193-200. PubMed ID: 20512579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignancies.
    Argiris A; Feinstein TM; Wang L; Yang T; Agrawal S; Appleman LJ; Stoller RG; Grandis JR; Egloff AM
    Invest New Drugs; 2012 Aug; 30(4):1575-84. PubMed ID: 21881918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual inhibition of the epidermal growth factor receptor pathway with cetuximab and erlotinib: a phase I study in patients with advanced solid malignancies.
    Guarino MJ; Schneider CJ; Hosford MA; Brahmer JR; Rudin CM; Finckenstein FG; Philip-Norton RE; Lu H; Weber MR; Ettinger DS
    Oncologist; 2009 Feb; 14(2):119-24. PubMed ID: 19182243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.